CL2013003044A1 - Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de quinasa mps-1; composicion farmaceutica; procedimiento de preparacion; combinacion farmaceutica; compuestos intermediarios; y uso para la profilaxis o tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis y leucemias, entre otras enfermedades. - Google Patents

Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de quinasa mps-1; composicion farmaceutica; procedimiento de preparacion; combinacion farmaceutica; compuestos intermediarios; y uso para la profilaxis o tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis y leucemias, entre otras enfermedades.

Info

Publication number
CL2013003044A1
CL2013003044A1 CL2013003044A CL2013003044A CL2013003044A1 CL 2013003044 A1 CL2013003044 A1 CL 2013003044A1 CL 2013003044 A CL2013003044 A CL 2013003044A CL 2013003044 A CL2013003044 A CL 2013003044A CL 2013003044 A1 CL2013003044 A1 CL 2013003044A1
Authority
CL
Chile
Prior art keywords
compounds
tumor
mps
triazolo
leukemias
Prior art date
Application number
CL2013003044A
Other languages
English (en)
Spanish (es)
Inventor
Gerhard Siemeister
Antje Margret Wengner
Volker Schulze
Dirk Kosemund
Hartmut Schirok
Hans Briem
Detlef Stockigt
Philip Lienau
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CL2013003044A1 publication Critical patent/CL2013003044A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2013003044A 2011-04-21 2013-10-21 Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de quinasa mps-1; composicion farmaceutica; procedimiento de preparacion; combinacion farmaceutica; compuestos intermediarios; y uso para la profilaxis o tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis y leucemias, entre otras enfermedades. CL2013003044A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11163342 2011-04-21
EP11167872 2011-05-27

Publications (1)

Publication Number Publication Date
CL2013003044A1 true CL2013003044A1 (es) 2014-05-02

Family

ID=46124297

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003044A CL2013003044A1 (es) 2011-04-21 2013-10-21 Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de quinasa mps-1; composicion farmaceutica; procedimiento de preparacion; combinacion farmaceutica; compuestos intermediarios; y uso para la profilaxis o tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis y leucemias, entre otras enfermedades.

Country Status (39)

Country Link
US (1) US20140120087A1 (https=)
EP (1) EP2699575B1 (https=)
JP (1) JP5989091B2 (https=)
KR (1) KR20140025470A (https=)
CN (1) CN103608350B (https=)
AP (1) AP3491A (https=)
AR (1) AR086191A1 (https=)
AU (1) AU2012244859B2 (https=)
CA (1) CA2833657A1 (https=)
CL (1) CL2013003044A1 (https=)
CO (1) CO6801751A2 (https=)
CR (1) CR20130539A (https=)
CY (1) CY1116439T1 (https=)
DK (1) DK2699575T3 (https=)
DO (1) DOP2013000244A (https=)
EA (1) EA023766B1 (https=)
EC (1) ECSP13013011A (https=)
ES (1) ES2539265T3 (https=)
GT (1) GT201300254A (https=)
HR (1) HRP20150517T1 (https=)
HU (1) HUE025496T2 (https=)
IL (1) IL228704A0 (https=)
JO (1) JO3040B1 (https=)
MA (1) MA35049B1 (https=)
ME (1) ME02143B (https=)
MX (1) MX348783B (https=)
MY (1) MY164939A (https=)
PE (1) PE20141351A1 (https=)
PH (1) PH12013502169A1 (https=)
PL (1) PL2699575T3 (https=)
PT (1) PT2699575E (https=)
RS (1) RS54044B1 (https=)
SA (1) SA112330466B1 (https=)
SG (1) SG194003A1 (https=)
SI (1) SI2699575T1 (https=)
TW (1) TWI558703B (https=)
UY (1) UY34034A (https=)
WO (1) WO2012143329A1 (https=)
ZA (1) ZA201308707B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013027096A2 (pt) 2011-04-21 2016-12-27 Gilead Sciences Inc compostos de benzotiazol e seu uso farmacêutico
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
CN104284896B (zh) 2012-03-14 2016-06-01 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
CA2878481A1 (en) 2012-07-10 2014-01-16 Bayer Pharma Aktiengesellschaft Method for preparing substituted triazolopyridines
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014195274A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines
JP2016527193A (ja) * 2013-06-07 2016-09-08 バイエル・ファルマ・アクティエンゲゼルシャフト 置換トリアゾロピリジン
SG11201509351UA (en) * 2013-06-10 2015-12-30 Bayer Pharma AG Novel compounds for the treatment of cancer
HK1219879A1 (zh) * 2013-06-11 2017-04-21 Bayer Pharma Aktiengesellschaft 用於治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合
RS56034B1 (sr) * 2013-06-11 2017-09-29 Bayer Pharma AG Derivati prolekova supstituisanih triazolopiridina
EP2860177A3 (en) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
FI3283642T3 (fi) 2015-04-17 2024-01-11 Crossfire Oncology Holding B V Prognostisia biomarkkereita ttk-inhibiittorikemoterapiaan
CN109963854B (zh) * 2017-03-16 2022-04-12 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
NZ780966A (en) 2019-04-18 2026-02-27 Univ Johns Hopkins Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
MX2007001943A (es) 2004-08-17 2007-05-09 Galderma Res & Dev Nuevos compuestos biaromaticos activadores de los receptores del tipo receptor activado del proliferador de peroxisoma (ppar) y su uso en composiciones cosmeticas o farmaceuticas.
JP5336375B2 (ja) * 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
US8053574B2 (en) 2007-07-18 2011-11-08 Novartis Ag Organic compounds
MX2010002115A (es) 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
CA2691448A1 (en) * 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
MX2010005700A (es) * 2007-11-27 2010-06-11 Cellzome Ltd Amino triazoles como inhibidores pi3k.
SG173610A1 (en) 2009-02-13 2011-09-29 Fovea Pharmaceuticals Sa [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
CN102413831B (zh) 2009-04-29 2014-06-04 拜耳知识产权有限责任公司 取代的咪唑并喹喔啉
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas

Also Published As

Publication number Publication date
AU2012244859A1 (en) 2013-10-31
EA023766B1 (ru) 2016-07-29
AU2012244859B2 (en) 2017-06-08
IL228704A0 (en) 2013-12-31
TW201245194A (en) 2012-11-16
AR086191A1 (es) 2013-11-27
TWI558703B (zh) 2016-11-21
HUE025496T2 (en) 2016-04-28
HK1190398A1 (zh) 2014-07-04
EP2699575B1 (en) 2015-03-25
DK2699575T3 (da) 2015-06-22
CO6801751A2 (es) 2013-11-29
CA2833657A1 (en) 2012-10-26
JP2014511887A (ja) 2014-05-19
ES2539265T3 (es) 2015-06-29
SI2699575T1 (sl) 2015-10-30
PT2699575E (pt) 2015-07-29
JP5989091B2 (ja) 2016-09-07
NZ616456A (en) 2015-09-25
MY164939A (en) 2018-02-15
EA201301181A1 (ru) 2014-08-29
WO2012143329A1 (en) 2012-10-26
MX348783B (es) 2017-06-28
ME02143B (me) 2015-10-20
SG194003A1 (en) 2013-11-29
ECSP13013011A (es) 2013-12-31
RS54044B1 (sr) 2015-10-30
AP2013007182A0 (en) 2013-10-31
AP3491A (en) 2015-12-31
CN103608350A (zh) 2014-02-26
GT201300254A (es) 2015-09-01
EP2699575A1 (en) 2014-02-26
CR20130539A (es) 2013-12-04
HRP20150517T1 (hr) 2015-06-19
US20140120087A1 (en) 2014-05-01
KR20140025470A (ko) 2014-03-04
PE20141351A1 (es) 2014-11-01
DOP2013000244A (es) 2014-03-16
ZA201308707B (en) 2016-07-27
SA112330466B1 (ar) 2015-09-28
CN103608350B (zh) 2015-11-25
MA35049B1 (fr) 2014-04-03
JO3040B1 (ar) 2016-09-05
PH12013502169A1 (en) 2014-01-13
CY1116439T1 (el) 2017-02-08
PL2699575T3 (pl) 2015-08-31
MX2013012289A (es) 2013-11-21
UY34034A (es) 2012-11-30

Similar Documents

Publication Publication Date Title
CL2013003044A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de quinasa mps-1; composicion farmaceutica; procedimiento de preparacion; combinacion farmaceutica; compuestos intermediarios; y uso para la profilaxis o tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis y leucemias, entre otras enfermedades.
CL2013002430A1 (es) Compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de proteina kinasa trk; composicion farmaceutica; compuesto intermediarios; utiles para el tratamiento de carcinoma pailar de tiroides, cancer de pancreas, cancer de colon y carcinoma de mama, entre otras.
MX2019003605A (es) Formas solidas de un inhibidor de cdk4/6 selectivo.
CL2014001103A1 (es) Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros.
HUE061909T2 (hu) Pirazolo[1,5-a]pirimidinek alkalmazása ATR kináz inhibítorként, rákos megbetegedések kezelésére
HUE053067T2 (hu) Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
ZA201700035B (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
SI3077397T1 (sl) 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)pirazolo(1,5-A)pirimidin-3- karboksamidna spojina, koristna kot inhibitor kinaze ATR, njena priprava, različne trdne oblike in njeni radioaktivno označeni derivati
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
EA201491456A1 (ru) Соединения-ингибиторы raf
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
DK3489238T3 (da) Farmaceutiske sammensætninger af 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-on- og [1,2,4]triazolo[1,5-c]pteridin-5(6h)-on-derivater som pde1-inhibitorer til behandling af for eksempel neurologiske lidelser
BR112012023660B8 (pt) usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer
CL2014001060A1 (es) Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.
CL2015000408A1 (es) Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer.
HUE057317T2 (hu) Helyettesített [1,2,4]triazolo[1,5-A]pirimidin-7-IL vegyületeket tartalmazó készítmények mint PDE2 inhibítorok
PT3177659T (pt) Compostos contendo azoto, adequados para uso na preparação de poliuretanos
CL2014000203A1 (es) Compuestos derivados de piridin-2(1h) -ona, inhibidores de jak; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento de enfermedades mieloproliferativas, leucemia,artritid reumatoide, asma, esclerosis multiplem, entre otras.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
CR20170315A (es) Inhibridores bace 1 selectivos
EP2861608B8 (en) Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
EA201490283A1 (ru) Соли азабициклических диариловых эфиров и способы их получения или получения их предшественников
WO2013188750A3 (en) Substituted macrocyclic compounds having proteasome inhibitory activity